Evidence map›Paper›PMID 40937822›Full record

ArticlePediatric blood & cancer2025

Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors.

Matthew E Campbell, Sonja Stutzman, Sharon Primeaux, Deseray Sida, Minjae Lee, Avanthi T Shah, Arhanti Sadanand, Elizabeth Sokol, Natalie B Collins, Brian Turpin and 7 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04796012 (VITAS), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04796012 phase1 / phase2recruitingnot on this map

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors: An Open-label, Phase II, Single-arm, Multi-center Trial

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2023 to 2027Enrolled23ConditionsSolid Tumor, RhabdomyosarcomaArmsAtezolizumab, Vincristine, Irinotecan, Temozolomide
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Matthew E CampbellDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0009-0000-4497-7364
Sonja StutzmanDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Sharon PrimeauxDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0009-0000-7358-8210
Deseray SidaDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Minjae LeeDepartment of Health Data Science & Biostatistics, Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0002-4329-506X
Avanthi T ShahDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Arhanti SadanandDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0002-7780-1688
Elizabeth SokolDivision of Hematology, Oncology, and Stem Cell Transplantation, Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-1787-6901
Natalie B CollinsDana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA.
Brian TurpinPediatric Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0002-3658-5659
Shoba NavaiDivision of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-1220-2788
Katie AlbertDivision of Hematology/Oncology, Department of Pediatrics, University of Washington, Seattle, Washington, USA.
Theodore W LaetschDivision of Hematology/Oncology, Department of Pediatrics, University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Dinesh RakhejaDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0001-6888-7902
Kenneth S ChenDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID https://orcid.org/0000-0003-2304-4631
David E GerberDivision of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Andrew Y KohDivision of Hematology/Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Funding

Mentoring Patient Oriented Research in the Microbiome of Cancer and Stem Cell Transplant PatientsK24AI150992 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI KOH, ANDREW · 2020 to 2024
$592k
Alex's Lemonade Stand Foundation for Childhood CancerChildren's Cancer FundChildren's HealthNIAID NIH HHS K24 AI150992University of Texas Southwestern Medical CenterV FoundationWipe Out Kids' Cancer
6 · The paper itself

Abstract

backgroundCombining immune checkpoint inhibitors (ICI) with chemotherapy may improve treatment response in children with solid tumors. We sought to determine the feasibility of combining vincristine, irinotecan, and temozolomide with the ICI atezolizumab in children with relapsed or refractory solid tumors (VITAS;).

methodsPatients ≥6 months and ≤18 years old with a relapsed or refractory solid tumor, no prior ICI, and evaluable disease per RECIST v1.1 were eligible for the Phase I cohort (NCT04796012). Patients received atezolizumab 15 mg/kg on Day 1, vincristine 1.5 mg/m

resultsSix patients (median age: 14 years) with rhabdomyosarcoma (n = 3), osteosarcoma (n = 2), and Ewing sarcoma (n = 1) received therapy and were evaluable for toxicity. Patients received a median of seven (range: 2-20) cycles of treatment. No patients experienced a DLT. One patient experienced Grade 2 immune-related colitis. Four patients experienced Grade ≥3 adverse events (decreased neutrophil count, febrile neutropenia, weight loss, anorexia). One patient with rhabdomyosarcoma had a sustained partial response through 16 cycles. One patient with relapsed pulmonary osteosarcoma has ongoing stable disease through 20 cycles.

conclusionsAtezolizumab combined with vincristine, irinotecan, and temozolomide was feasible and well tolerated in children with solid tumors. Efficacy of this regimen is now being assessed in relapsed and refractory rhabdomyosarcoma in an ongoing Phase II cohort.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalNeoplasmsRhabdomyosarcomaAdolescentAntibodies, Monoclonal, HumanizedChildChild, PreschoolDrug Resistance, NeoplasmFeasibility StudiesFemaleFollow-Up StudiesHumansInfantIrinotecanMaleAntibodies, Monoclonal, HumanizedatezolizumabIrinotecanTemozolomideVincristinecombination therapyimmunotherapyphase I trialsarcomasolid tumors

Identifiers

PMID40937822
PMCPMC13445394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.